Ovarian cancer remains one of the most lethal gynecologic malignancies, claiming the lives of more than 13,000 women in the United States each year. [1] Notoriously difficult to detect in the early stages, nearly 80% of ovarian cancer patients are diagnosed at stage III or IV when the disease is already advanced and is often too late to effectively treat.[2] Across disease stages, nearly half of those diagnosed will not survive beyond five years. [3]
Despite this high disease prevalence and mortality rate, the current standard of care for ovarian cancer, platinum-based chemotherapy, has remained largely unchanged since the 1960s. There is an urgent need for more safe, targeted therapeutics and innovative treatment strategies to increase both progression-free and overall survival outcomes for women with advanced ovarian cancer. Many researchers have explored the development of immunotherapies that harness interleukin-12 (IL-12), a well-validated and potent cytokine that has significant potential to reshape the tumor microenvironment and activate anti-tumor immunity, driving meaningful outcomes in this historically difficult-to-treat disease.
The Decades-Long Journey to Harness IL-12 for Cancer
Cytokines and interleukins are essential molecular messengers facilitating communication within the immune system. These signaling proteins play a crucial role in coordinating the behavior of immune cells by either enhancing or reducing inflammation, recruiting cells to specific areas of the body, or organizing targeted responses against infections or diseases. While several cytokine-based immunotherapies have previously been approved for a range of other serious diseases, the broader category of interleukins has not yet realized its full therapeutic potential in cancer including ovarian cancer. Among these, IL-12 has been established as a promising target for the treatment of advanced solid tumors.
IL-12 is a potent signaling molecule that connects innate and adaptive immunity. It enhances the proliferation and activation of T-lymphocytes and natural killer cells, which are essential components in the body’s defense against tumors. [4] Additionally, IL-12 increases interferon-gamma production, a key cytokine that enhances immune responses and antigen presentation. Beyond its immunostimulatory effects, IL-12 has also shown the ability to inhibit tumor angiogenesis, the process through which tumors develop their own blood supply. [5]
The role of IL-12 as an immune amplifier has been well-established in preclinical cancer studies over the last several decades. Since its discovery in 1989, IL-12 has demonstrated the ability to slow or even eliminate tumor growth in animal models. [5] These early successes generated significant clinical interest in IL-12 immunotherapies during the 1990s and early 2000s.
However, initial clinical trials of these drugs failed to deliver on IL-12’s potential, with only modest anti-tumor effects presumably due to low bioavailability at the tumor site and serious toxicity. Systemic administration of IL-12 immunotherapies was shown to be associated with significant and sometimes dangerous dose-limiting toxicities, such as cytokine release syndrome, posing serious risks to patient safety. These challenges hindered progress in the field, but they also highlighted an essential insight, that IL-12’s strength lies in its precise application.[6]
Researchers learned the lesson that to fully harness the therapeutic potential of IL-12, it must be delivered directly to the tumor site in a controlled, localized, and temporary manner. This approach ensures that IL-12 is powerful only where and when it is needed. Success hinges on achieving a balance between the potent immune-stimulating effects of IL-12 and minimizing off-target systemic toxicities.
Solving the IL-12 Delivery Challenge
A critical challenge has often limited the promise of IL-12 in treating cancer: How can this potent cytokine be delivered directly to the tumor site, for the appropriate duration, killing tumor cells without harming healthy cells and tissues? TheraPlas™, a proprietary non-viral nanoparticle delivery platform, may be the solution to achieving that goal.
TheraPlas is designed to safely and effectively engineer cells to produce therapeutic proteins specifically at the tumor site. Unlike traditional viral vectors, TheraPlas delivers IL-12-encoding DNA plasmids directly into the local tumor microenvironment, avoiding the risks associated with systemic viral integration and repeatability challenges due to anti-viral immunity. By focusing specifically on the local tumor environment and optimizing IL-12 delivery, there is significant potential to drive robust anti-tumor responses while substantially reducing the risk of toxic off-target effects and adverse events for patients.
Targeting Advanced Ovarian Cancer
Researchers are currently advancing an IL-12 based immunotherapy delivered using the TheraPlas approach in a Phase 3 trial for the potential treatment of women with newly diagnosed advanced (stage III or IV) ovarian cancer when used in combination with standard of care chemotherapy. The therapy aims to train the body to combat cancer from within, coaching cells in the peritoneal cavity to produce IL-12 in a controlled manner, right at the disease site. This protects the DNA payload from degradation and enhances cellular uptake, leading to more effective and sustained production of cytokines at the right place at the right time.
Data from a Phase 2 study, called OVATION 2(NCT03393884) found that women who were treated with this novel IL-12 immunotherapy (IMNN-001), in combination with standard of care neoadjuvant and adjuvant chemotherapy, experienced a median overall survival increase of 13 months compared to those receiving standard of care alone (46 months vs. 33 months; HR 0.69). Treated women also achieved a median 3-month improvement in progression-free survival (14.9 months vs. 11.9 months; HR 0.79), with all patients treated with IMNN-001 remaining progression-free while on treatment, surpassing conventional thresholds for clinical significance. [7]
Additional analyses showed a particularly positive response in specific sub-populations. Among patients who received PARP inhibitors, which are widely used as part of maintenance therapy for ovarian cancer, progression-free survival increased by nearly 12 months (33.8 months compared to 22.1 months; HR 0.8). Furthermore, the median overall survival in the group receiving the IL-12 immunotherapy had not yet been reached after more than five years, in contrast to 37 months in the control group (HR 0.38). Study participants with homologous recombination deficiency, including those with BRCA1/2 mutations, also experienced significant improvements (HR 0.42), indicating a strong response within genetically defined populations.
IMNN-001 also appears to be well tolerated. Studies to date have shown no signs of cytokine release syndrome, systemic toxicity, or serious immune-related adverse events unlike other IL-12 immunotherapies. The most common side effects were local and limited to abdominal pain, nausea, and vomiting. These results reinforce the potential to safely harness IL-12 by delivering to the local tumor microenvironment while achieving higher levels of efficacy benefit when used in conjunction with current standard of care treatment protocols.
Moving Toward a New Standard in Ovarian Cancer
The promising results from the Phase 2 OVATION 2 Study represent a significant advance in ovarian cancer, and the first time that, with a favorable safety profile, an immunotherapy achieved clinically effective survival benefits in this patient population in a first-line setting when combined with standard of care chemotherapy. If results can be replicated in a Phase 3 pivotal trial, it will further validate the potential of this investigational immunotherapy and demonstrate that it is possible to safely and effectively harness the powerful cytokine properties of IL-12 to treat ovarian cancer.
This research offers hope to the thousands of women living with advanced ovarian cancer, one of the most challenging cancers in women’s health, and that they may soon have a targeted, durable, and safer immunotherapy option that will lead to more birthdays, more holidays, and more moments with loved ones in the years ahead.
Clinical trials
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) (OVATION 2) – ClinicalTrials.gov ID NCT03393884
Reference
[1] Mahoney DE, Pierce JD. Ovarian Cancer Symptom Clusters: Use of the NIH Symptom Science Model for Precision in Symptom Recognition and Management. Clin J Oncol Nurs. 2022 Sep 15;26(5):533-542. doi: 10.1188/22.CJON.533-542. PMID: 36108208; PMCID: PMC9951395.
[2] El Housheimi A, Tato Varela S, Kuhn WC. Prognosis and Therapy of Ovarian Cancer, Part 3: Follow up care, recurrence and screening, the full round circle. Oncol Res Treat. 2025 Jul 5:1-18. doi: 10.1159/000547282. Epub ahead of print. PMID: 40618729.
[3] Cancer Stat Facts: Ovarian Cancer. National Cancer Institute (NCI). Online. Last accesses on July 25, 2025.
[4] Lasek W, Zagożdżon R, Jakobisiak M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother. 2014 May;63(5):419-35. doi: 10.1007/s00262-014-1523-1. Epub 2014 Feb 11. PMID: 24514955; PMCID: PMC3994286.
[5] Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum K, Vom Berg J, Kulig P, Becher B. New insights into IL-12-mediated tumor suppression. Cell Death Differ. 2015 Feb;22(2):237-46. doi: 10.1038/cdd.2014.134. Epub 2014 Sep 5. PMID: 25190142; PMCID: PMC4291488.
[6] Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022 Feb;22(2):85-96. doi: 10.1038/s41577-021-00547-6. Epub 2021 May 17. PMID: 34002066; PMCID: PMC8127450.
[7] Thaker PH, Richardson DL, Hagemann AR, Holloway RW, Reed M, Bergman MK, Pothuri B, DePasquale S, Scalici JM, Bregar AJ, Darus CJ, Finkelstein K, Leath CA 3rd, Bell M, Warshal DP, Agajanian R, Indermaur MD, Mendivil AA, Provencher DM, Wei LJ, Borys N, Musso L, Lindborg SR, Faller DV, Anwer K, Bradley WH. OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer. Gynecol Oncol. 2025 Jun;197:182-191. doi: 10.1016/j.ygyno.2025.04.578. Epub 2025 Jun 3. PMID: 40461366.
Featured image: Women suffering from ovarian cancer. Photo courtesy: © 2019 Fotolia/Adobe. Used with permission.
DOI





